Revenue plunges, stock takes a drubbing, but Teva CEO Kåre Schultz still grabs $32.5M in chart-topping compensation
Teva CEO Kåre Schultz hasn’t managed to turn the ship around at Teva, but that didn’t stop him from becoming the highest paid Big Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
